$QURE

Kaye Jack sold $225K of QURE

Kaye Jack sold 5,295 shares of uniQure N.V. (QURE) at $42.57 ($0.23M total) on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kaye Jack
Published Jun 22, 2026, 11:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest concrete fact is the director’s open-market sale of 5,295 shares at $42.57 on 2026-06-17, with holdings after the trade and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 structure makes it more of a sentiment datapoint than a fundamental catalyst.

03

What to watch

The filing doesn’t disclose new company performance, guidance, or risk changes—so traders should avoid over-weighting it versus upcoming catalysts (earnings/clinical/regulatory).

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-22 after-hours/early session; reflects sale dated 2026-06-17.

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure director Kaye Jack sold 5,295 shares in an open-market transaction on 2026-06-17 for about $225.4K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, which typically reduces signaling value versus discretionary sales.

Market effects

Minimal; single-company insider sale without clinical/regulatory updates provides no sector read-through.

None indicated; event is company-specific and small relative to market cap.

None indicated; no cross-border deal/regulatory action described.

Counterpoint

Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • uniQure N.V.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Kaye Jack

    Director who sold shares under an open-market transaction tied to a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.